Drugs / CBD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04261166 | Jul 2019 → Oct 2022 | — | Breath of Life International Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBD | “Sublingual tablets. CBD 40 mg (1 tablet)” NCT04261166 ↗ |